23,961 Shares in Septerna, Inc. $SEPN Acquired by Nuveen LLC

Key Points

• Nuveen LLC acquired 23,961 shares of Septerna, Inc. valued at approximately $139,000, representing around 0.05% of the company.
• Septerna reported a loss of ($0.56) earnings per share for the last quarter, significantly missing the consensus estimate of ($0.05), and generated $0.12 million in revenue versus expectations of $22.50 million.
• Analysts have set a consensus target price of $26.75 for Septerna, with Cantor Fitzgerald and HC Wainwright assigning "overweight" and "buy" ratings, respectively.

Nuveen LLC acquired a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,961 shares of the company's stock, valued at approximately $139,000. Nuveen LLC owned about 0.05% of Septerna as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SEPN. Swiss National Bank bought a new stake in shares of Septerna in the first quarter valued at approximately $174,000. Deutsche Bank AG raised its stake in Septerna by 53.3% during the first quarter. Deutsche Bank AG now owns 15,968 shares of the company's stock worth $92,000 after acquiring an additional 5,549 shares in the last quarter. TRV GP VI LLC raised its stake in Septerna by 33.6% during the first quarter. TRV GP VI LLC now owns 4,211,659 shares of the company's stock worth $24,386,000 after acquiring an additional 1,059,203 shares in the last quarter. Chicago Partners Investment Group LLC acquired a new position in Septerna during the first quarter worth $63,000. Finally, XTX Topco Ltd acquired a new position in Septerna during the first quarter worth $216,000.

Septerna Stock Performance

NASDAQ:SEPN opened at $14.43 on Friday. Septerna, Inc. has a fifty-two week low of $4.17 and a fifty-two week high of $28.99. The company has a market cap of $643.29 million and a price-to-earnings ratio of -1.43. The stock has a fifty day moving average price of $12.11 and a 200-day moving average price of $9.12.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.51). Septerna had a negative return on equity of 31.52% and a negative net margin of 12,053.03%.The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $22.50 million. Research analysts predict that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on SEPN shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price objective on shares of Septerna in a research note on Friday. HC Wainwright restated a "buy" rating and set a $26.00 target price on shares of Septerna in a report on Thursday, August 21st. Wells Fargo & Company raised their target price on Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a report on Friday, May 16th. Finally, Wall Street Zen upgraded Septerna from a "sell" rating to a "hold" rating in a research report on Friday. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $26.75.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

Want to see what other hedge funds are holding SEPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Septerna, Inc. (NASDAQ:SEPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.